Status:
UNKNOWN
RCA for CRRT in Hyperlactatemia Patient With Increased Bleeding Risk
Lead Sponsor:
Air Force Military Medical University, China
Conditions:
Continuous Renal Replacement Therapy
Hyperlactatemia
Eligibility:
All Genders
16+ years
Phase:
NA
Brief Summary
The purpose of this single center, randomized, control, open-labeled study is to evaluate the effect and safety of RCA versus no anticoagulation for CRRT in hyperlactatemia patients with increased ble...
Detailed Description
For continuous renal replacement therapy (CRRT) patients with shock and muscle hypoperfusion, which characterised by tissue hypoxia and hyperlactatemia, the Kidney Disease Improving Global Outcomes (K...
Eligibility Criteria
Inclusion
- Age≥16 years
- Hyperlactatemia (Lactic acid or serum lactate level \> 2 mmol/L)
- Required CRRT
- Increased bleeding risk: PLT \< 40 x 109, aPTT \> 60 s, INR \> 1.5, bleeding or active bleeding within 7 days, recent trauma or surgery (especially head trauma and neurosurgery), recent stroke, intracranial venous malformation or aneurysm, retinal hemorrhage, uncontrolled hypertension, and epidural catheter implantation.
Exclusion
- Drugs (biguanide, linezolid, cyanide, etc.) and congenital metabolic disorders (glucose-6 phosphatase and 1,6 phosphofructosase deficiency) and mitochondrial damage caused hyperlactatemia.
- Receiving systemic anticoagulant treatment (heparin/lmol/warfarin/aspirin, etc.) within 24 hours.
- Critical patients with lactic acid ≥15mmol\\L (with a mortality of 100%) were excluded
- Patients with APTT \> 100S were excluded (retrospective data suggested that this type of patients received CRRT treatment should last for more than 24 hours)
- Patients who are pregnant or during lactation
- Severe liver failure: child-pugh score \>10 (chronic severe liver failure), MELD score \> 30 (acute severe liver failure), total bilirubin \>51 mol/L
- Patients with internal fistula were treated with CRRT
- Unable to cooperate with treatment due to mental problems (such as depression and mental illness)
- CRRT with arteriovenous fistula, or the prescribed treatment time \< 12 hours
Key Trial Info
Start Date :
March 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 3 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04315623
Start Date
March 30 2020
End Date
March 3 2022
Last Update
March 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing Hospital of Nephrology
Xi'an, Shaanxi, China, 710032